EUVIMEDEUVIMED entdecken
Open Access

MARVEL: A Randomized Double‐Blind, Placebo‐Controlled Trial in Patients Undergoing Endovascular Therapy: Study Rationale and Design

Qingwu Yang, Changwei Guo, Chengsong Yue, Jie Yang, Linyu Li, Zhouzhou Peng, Jinrong Hu, Jiandi Huang, Jiaxing Song, Jiacheng Huang, Weilin Kong, Nizhen Yu und 7 weitere

Stroke: Vascular and Interventional Neurology · 2024-03 · 4 (2)

DOI: 10.1161/svin.123.001090 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stroke: Vascular and Interventional Neurology, 2024-03. Verfasst von Qingwu Yang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology Xinqiao Hospital Army Medical University Chongqing China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Steroids have pleiotropic neuroprotective actions including the regulation of inflammation and apoptosis which may influence the effects of ischemia on neurons, glial cells, and blood vessels. The effect of low‐dose methylprednisolone in patients with acute ischemic stroke in the endovascular therapy era remains unknown. This trial investigates the efficacy and safety of low‐dose methylprednisolone (2 mg/kg IV for 3 days) as adjunctive therapy for patients with acute ischemic stroke undergoing endovascular therapy within 24 hours from symptom onset.

Methods

The MARVEL (Methylprednisolone as Adjunctive Therapy for Acute Large Vessel Occlusion: A Randomized Double‐Blind, Placebo‐Controlled Trial in Patients Undergoing Endovascular Therapy) trial is an investigator‐initiated, prospective, randomized, double‐blind, placebo‐controlled multicenter clinical trial. Up to 1672 eligible patients with anterior circulation large‐vessel occlusion stroke presenting within 24 hours from symptom onset are planned to be consecutively randomized to receive methylprednisolone or placebo in a 1:1 ratio across 82 stroke centers in China.

Results

The primary outcome is the ordinal shift in the modified Rankin scale score at 90 days. Secondary outcomes include 90‐day functional independence (modified Rankin scale score, 0–2). The primary safety end points include mortality rate at 90 days and symptomatic intracerebral hemorrhage within 48 hours of endovascular therapy.

Conclusion

The MARVEL trial will provide evidence of the efficacy and safety of low‐dose methylprednisolone as adjunctive therapy for patients with anterior circulation large‐vessel occlusion stroke undergoing endovascular therapy.

Schlagwörter

Stichwörter der Autor:innen

adjunctive therapycorticosteroidsendovascular therapymethylprednisolonerandomized trialtrial protocol

Autor:innen und Institutionen

  • Department of Neurology Xinqiao Hospital Army Medical University Chongqing China.
  • Global Health Trials Unit Liverpool School of Tropical Medicine Liverpool UK.
  • UPMC Stroke Institute Departments of Neurology and Neurosurgery University of Pittsburgh School of Medicine PA.
  • Department of Neurology and Radiology Boston Medical Center Boston MA.

ORCID-Profile: Wenjie Zi

Zitieren

APA

Yang, Q., Guo, C., Yue, C., Yang, J., Li, L., Peng, Z., Hu, J., Huang, J., Song, J., Huang, J., Kong, W., Yu, N., Yang, D., Liu, X., Wang, D., Nogueira, R. G., Li, F., Nguyen, T. N., & Zi, W. (2024). MARVEL: A Randomized Double‐Blind, Placebo‐Controlled Trial in Patients Undergoing Endovascular Therapy: Study Rationale and Design. Stroke: Vascular and Interventional Neurology, 4(2). https://doi.org/10.1161/svin.123.001090

Vancouver

Yang Q, Guo C, Yue C, Yang J, Li L, Peng Z, et al. MARVEL: A Randomized Double‐Blind, Placebo‐Controlled Trial in Patients Undergoing Endovascular Therapy: Study Rationale and Design. Stroke: Vascular and Interventional Neurology. 2024;4(2). doi:10.1161/svin.123.001090

BibTeX
@article{Yang2024,
  author = {Yang, Qingwu and Guo, Changwei and Yue, Chengsong and Yang, Jie and Li, Linyu and Peng, Zhouzhou and Hu, Jinrong and Huang, Jiandi and Song, Jiaxing and Huang, Jiacheng and Kong, Weilin and Yu, Nizhen and Yang, Dahong and Liu, Xiang and Wang, Duolao and Nogueira, Raul G and Li, Fengli and Nguyen, Thanh N and Zi, Wenjie},
  title = {MARVEL: A Randomized Double‐Blind, Placebo‐Controlled Trial in Patients Undergoing Endovascular Therapy: Study Rationale and Design},
  journal = {Stroke: Vascular and Interventional Neurology},
  year = {2024},
  volume = {4},
  number = {2},
  doi = {10.1161/svin.123.001090}
}
Kostenlos starten →